<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-07-08T08:44:08Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/4BC4279D-3804-4FFB-854D-D589F07B8397" ns1:id="4BC4279D-3804-4FFB-854D-D589F07B8397"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/03DFEC9F-343D-445A-8814-B67AE99B7E17" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/03DFEC9F-343D-445A-8814-B67AE99B7E17" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2014-09-29T23:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/CE00FF68-ED9A-4EF8-BE1B-B632BB1A52E3" ns1:rel="FUND" ns1:start="2014-07-31T23:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">131685</ns2:identifier></ns2:identifiers><ns2:title>First-in-class fully-biodegradable DNA delivery system for biomedical research and safe gene therapy</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Feasibility Studies</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>The transfer of foreign DNA molecules inside cells is an essential laboratory technique routinely used in biomedical research and a promissing therapeutic approach to treat disorders caused by malfunctioning genes such as cystic fibrosis, inherited eye diseases and several kinds of cancer. Apart from the controversial virus-based carriers, DNA delivery can be achieved using chemical reagents with the ability to complex DNA molecules and translocate them into the cell cytoplasm. However, in vivo delivery is largely limited by the reagent toxicity, the DNA size and the target cell / tissue. In this feasibility study, DELIVERICS will investigate a novel biodegradable delivery system to achieve safe transfer of DNA inside cells in vivo. This unique tool will address a commercial opportunity that exists both in the R&amp;amp;D and Pharma sectors, where advanced delivery systems are required for R&amp;amp;D studies and for the therapeutic delivery of DNA-based biopharmaceuticals.</ns2:abstractText></ns2:project>